MAY SIMON
Known title: EVP, President, LSGCIK: 0001900904
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Bio‑Rad Leads in Recombinant Protein & Magnetic Bead Growth. The latest market report shows the recombinant protein manufacturing sector is expected to triple in revenue by 2030, with Bio‑Rad listed among the key players. A separate analysis projects the magnetic bead market to grow from $3.3 billion in 2025 to $7.4 billion by 2032, again naming Bio‑Rad as a leader. These developments highlight the company’s expanding role in both protein production and diagnostic reagent markets.
Transaction History
| A | ▼ Sell | Tax Withholding | 368 | $43K | 5/8/2026 | View on chart |
| A | ▼ Sell | Tax Withholding | 300 | $46K | 11/26/2025 | View on chart |
| A | ▲ Buy | Grant | 6,781 | $0 | 11/18/2025 | View on chart |
| A | ▼ Sell | Tax Withholding | 368 | $40K | 5/8/2025 | View on chart |
| A | ▲ Buy | Grant | 3,452 | $477K | 11/27/2024 | View on chart |
| A | ▲ Buy | Grant | 4,235 | $605K | 5/8/2024 | View on chart |
| BIO | ▲ Buy | Option Exercise | 600 | $0 | 9/4/2023 | View on chart |
| BIO | ▼ Sell | Tax Withholding | 295 | $116K | 9/4/2023 | View on chart |
| BIO | ▲ Buy | Option Exercise | 526 | $0 | 9/3/2023 | View on chart |
| BIO | ▼ Sell | Tax Withholding | 182 | $72K | 9/3/2023 | View on chart |
| BIO | ▲ Buy | Option Exercise | 409 | $0 | 9/2/2023 | View on chart |
| BIO | ▼ Sell | Tax Withholding | 142 | $56K | 9/2/2023 | View on chart |
| BIO | ▲ Buy | Option Exercise | 520 | $0 | 9/1/2023 | View on chart |
| BIO | ▼ Sell | Tax Withholding | 180 | $71K | 9/1/2023 | View on chart |
| BIO | ▲ Buy | Option Exercise | 371 | $0 | 9/1/2023 | View on chart |
| BIO | ▼ Sell | Tax Withholding | 129 | $51K | 9/1/2023 | View on chart |
| BIO | ▲ Buy | Option Exercise | 600 | $0 | 9/5/2022 | View on chart |
| BIO | ▼ Sell | Tax Withholding | 298 | $143K | 9/5/2022 | View on chart |
| BIO | ▲ Buy | Option Exercise | 600 | $0 | 9/4/2022 | View on chart |
| BIO | ▼ Sell | Tax Withholding | 285 | $136K | 9/4/2022 | View on chart |
| BIO | ▲ Buy | Option Exercise | 526 | $0 | 9/3/2022 | View on chart |
| BIO | ▼ Sell | Tax Withholding | 182 | $87K | 9/3/2022 | View on chart |
| BIO | ▲ Buy | Option Exercise | 409 | $0 | 9/2/2022 | View on chart |
| BIO | ▼ Sell | Tax Withholding | 142 | $68K | 9/2/2022 | View on chart |
| BIO | ▲ Buy | Option Exercise | 371 | $0 | 9/1/2022 | View on chart |
| BIO | ▼ Sell | Tax Withholding | 129 | $63K | 9/1/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Agilent to acquire Proscia for up to $270M
Agilent Technologies has agreed to acquire digital pathology specialist Proscia in a deal valued at up to $270 million. The move is designed to strengthen Agilent's position in AI-enabled diagnostics and scientific intelligence. Following the announcement, TD Cowen raised its price target for the stock to $196.
Agilent to acquire Proscia for up to $270M. Agilent Technologies has agreed to acquire digital pathology specialist Proscia in a deal valued at up to $270 million. The move is designed to strengthen Agilent's position in AI-enabled diagnostics and scientific intelligence. Following the announcement, TD Cowen raised its price target for the stock to $196.